Business context and reporting period
Kairos Pharma, Ltd. (NYSE American: KAPA) furnished an 8-K on October 6, 2026, reporting an event on that date. The company announced interim efficacy data from its ongoing Phase 2 trial of ENV-105 (carotuximab) combined with apalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).
Financial and operating metrics
This 8-K provides no revenue, earnings, cash flow, margin, debt, liquidity, or other financial results. It does not state numerical efficacy results or trial enrollment details.
Changes versus prior period
No comparative-period financial or operating data are provided. The filing identifies an interim clinical-trial data announcement but does not describe how the results compare with earlier data.
Outlook, risks, and unusual items
The filing contains no financial guidance or management outlook. The detailed announcement is identified as Exhibit 99.1, but its press-release text is not included in the provided filing content. The 8-K states that the information, including the exhibit, is furnished and generally is not deemed filed for purposes of Exchange Act Section 18 or incorporated into other filings unless specifically referenced.
Important facts to verify
- Review Exhibit 99.1 for the actual efficacy findings, data cutoff, patient population, endpoints, and any safety information.
- Verify trial size, follow-up duration, statistical analyses, and whether the interim findings are preliminary.
- Check subsequent company disclosures for trial status, next milestones, and any changes to the development plan.